Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis

Journal of Molecular Diagnostics

Volumn 11, Issue 5, 2009, Pages 482-487

  Mattarucchi, Elia ^a   Spinelli, Orietta ^b   Rambaldi, Alessandro ^b   Pasquali, Francesco ^a   Lo Curto, Francesco ^a   Campiotti, Leonardo ^a   Porta, Giovanni ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GENOMIC DNA; IMATINIB; MESSENGER RNA;

ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PRACTICE; DNA DETERMINATION; DRUG DOSE INCREASE; HUMAN; MINIMAL RESIDUAL DISEASE; RNA ANALYSIS; TREATMENT RESPONSE;

DNA; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES; RNA, MESSENGER;

EID: 70249092623     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.2353/jmoldx.2009.080150     Document Type: Article

References (31)

1. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007, 7:441-453 (Pubitemid 46823444)
2. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432 (Pubitemid 37211057)
3. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL: Punish the parent not the progeny. Blood 2005, 105:1862-1866
4. Mughal TI, Yong A, Szydlo RM, Dazzi F, Olavarria E, van Rhee F, Kaeda J, Cross NC, Craddock C, Kanfer E, Apperley J, Goldman JM: Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 2001, 115:569-574 (Pubitemid 34015646)
5. Cortes J, O'Brien S, Kantarjian H: Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004, 104:2204-2205 (Pubitemid 39297882)
6. Usuki K, Iijima K, Iki S, Urabe A: CML cytogenetic relapse after cessation of imatinib therapy. Leuk Res 2005, 29:237-238 (Pubitemid 39647521)
7. Deininger MW, O'Brien SG, Ford JM, Druker BJ: Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003, 21:1637-1647 (Pubitemid 46594119)
8. Goldman J: Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients? Nat Clin Practice Oncol 2005, 2:126-127
9. Goldman J: Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 2005, 12:33-39 (Pubitemid 40189237)
10. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809-1820 (Pubitemid 44394987)
11. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103:2873-2878 (Pubitemid 38451654)
12. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes T: Realtime quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004, 104:2926-2932 (Pubitemid 39434981)
13. Wang L, Knight K, Lucas C, Clark RE: The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006, 91:235-239 (Pubitemid 43304144)
14. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92:3362-3367 (Pubitemid 28492345)
15. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995, 86:3118-3122
16. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, Barbany G, Cazzaniga G, Cayuela JM, Cavé H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, González M, Viehmann S, Malec M, Saglio G, van Dongen JJ: Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17:2318-2357
17. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for "harmonizing" current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37
18. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 2003, 17:2474-2486
19. Müller MC, Hördt T, Paschka P, Merx K, La Rosée P, Hehlmann R, Hochhaus A: A standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol 2004, 112:30-33 (Pubitemid 38716247)
20. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL: Primitive, quiescent Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325
21. Kavalerchik E, Goff D, Jamieson CH: Chronic myeloid leukemia stem cells. J Clin Oncol 2008, 10:2911-2915
22. Savona M, Talpaz M: Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008, 8:341-350 (Pubitemid 351589698)
23. Goldman J, Gordon M: Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leukemia Lymphoma 2006, 47:1-7
24. Barnes DJ, Melo VJ: Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006, 5:2862-2866
25. Zhang JG, Lin F, Chase A, Goldman JM, Cross NC: Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996, 87:2588-2593 (Pubitemid 26086906)
26. Mattarucchi E, Guerini V, Rambaldi A, Campiotti L, Venco A, Pasquali F, Lo Curto F, Porta G: Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia. Genes Chromosomes Cancer 2008, 47:625-632 (Pubitemid 351748348)
27. Mattarucchi E, Marsoni M, Passi A, Lo Curto F, Pasquali F, Porta G: Establishment and study of different real-time polymerase chain reaction assays for the quantification of cells with deletions of chromosome 7. J Mol Diagn 2006, 8:218-224 (Pubitemid 43811245)
28. Porta G, Mattarucchi E, Maserati E, Pressato B, Valli R, Morerio C, Zecca M, Panarello C, Locatelli F, Lo Curto F, Pasquali F: Monitoring the isochromosome i(7)(q10) in the bone marrow of patients with Shwachman syndrome by real-time quantitative PCR. J Pediatr Hematol Oncol 2007, 29:163-165
29. Porta G, Maserati E, Mattarucchi E, Minelli A, Pressato B, Valli R, Zecca M, Bernardo ME, Lo Curto F, Locatelli F, Danesino C, Pasquali F: Monosomy 7 in myeloid malignancies: parental origin and monitoring by real-time quantitative PCR. Leukemia 2007, 21:1833-1835 (Pubitemid 47086778)
30. Hughes T, Branford S: Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006, 20:29-41 (Pubitemid 43106716)
31. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, Blanchet O, Marit G, Gluckman E, Reiffers J, Gardembas M, Mahon FX: Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood 2007, 109:58-60 (Pubitemid 46053043)